TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 9389379

Group type: EXPERIMENTAL
Intervention: Acadesine (5, 10, 20, 50 mg/kg i.v.)
Number of subjects: 47

Group type: COMPARATOR
Intervention: Control pacing (placebo)
Number of subjects: 47
Study: 7955799

Group type: EXPERIMENTAL
Intervention: MK-383 administered as 1-hour infusion at 0.25 microgram/kg/min
Number of subjects: 56

Group type: EXPERIMENTAL
Intervention: MK-383 administered as 4-hour infusion at 0.15 microgram/kg/min
Number of subjects: 56

Group type: EXPERIMENTAL
Intervention: MK-383
Number of subjects: 56

Group type: COMPARATOR
Intervention: Aspirin pretreatment (325 mg)
Number of subjects: 56
Study: 3454679

Group type: EXPERIMENTAL
Intervention: Memory training combined with oral physostigmine
Number of subjects: 2

Group type: COMPARATOR
Intervention: Placebo (control)
Number of subjects: 2
Study: 31752916

Group type: EXPERIMENTAL
Intervention: Workplace sitting-reduction intervention
Number of subjects: 198

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 198

Group type: EXPERIMENTAL
Intervention: Overall changes
Number of subjects: 198

Group type: EXPERIMENTAL
Intervention: Changes outside of work
Number of subjects: 198
Study: 27837048

Group type: EXPERIMENTAL
Intervention: Rituximab early drug (week 0/1)
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Rituximab late arms (week 8/9)
Number of subjects: 120

Group type: COMPARATOR
Intervention: Rituximab (early vs late)
Number of subjects: 120
Study: 25421877

Group type: EXPERIMENTAL
Intervention: MAP regimen (cisplatin 120 mg/m², doxorubicin 75 mg/m², methotrexate 12 g/m² × 2) pre-operatively followed by MAP or MAP with ifosfamide and etoposide post-operatively for patients with ≥10% viable tumour.
Number of subjects: 2260

Group type: EXPERIMENTAL
Intervention: MAP regimen followed by pegylated interferon for patients with <10% viable tumour.
Number of subjects: 2260

Group type: EXPERIMENTAL
Intervention: Pre-operative chemotherapy (MAP regimen)
Number of subjects: 2260
Study: 21917481

Group type: EXPERIMENTAL
Intervention: Minimally invasive procedures (MI group)
Number of subjects: 43

Group type: COMPARATOR
Intervention: Medical treatment (MT group)
Number of subjects: 43
Study: 21809156

Group type: EXPERIMENTAL
Intervention: Epi-No Birth Trainer
Number of subjects: 200
Study: 18365794

Group type: EXPERIMENTAL
Intervention: Cognitive Behavioral Therapy (CBT)
Number of subjects: 64
Study: 16480570

Group type: EXPERIMENTAL
Intervention: Cognitive behavioural guided self-care with personalized feedback
Number of subjects: 61

Group type: COMPARATOR
Intervention: Cognitive behavioural guided self-care without personalized feedback
Number of subjects: 61
Study: 12351463

Group type: EXPERIMENTAL
Intervention: Insulin alone
Number of subjects: 88

Group type: EXPERIMENTAL
Intervention: Insulin plus metformin
Number of subjects: 88

Group type: EXPERIMENTAL
Intervention: Insulin plus troglitazone
Number of subjects: 88

Group type: COMPARATOR
Intervention: Insulin plus metformin vs Insulin plus troglitazone
Number of subjects: 88
Study: 9926890

Group type: EXPERIMENTAL
Intervention: Misgav Ladach method
Number of subjects: 50

Group type: COMPARATOR
Intervention: Pfannenstiel method
Number of subjects: 50
Study: 7675941

Group type: EXPERIMENTAL
Intervention: Lorazepam 0.038 mg/kg
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Lorazepam 0.026 mg/kg
Number of subjects: 0
Study: 2288138

Group type: EXPERIMENTAL
Intervention: Fluid intake of less than 500 ml beverages per day
Number of subjects: 8

Group type: COMPARATOR
Intervention: Fluid intake of more than 2500 ml beverages per day
Number of subjects: 8
Study: 6986899

Group type: EXPERIMENTAL
Intervention: Clobetasone butyrate
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Prednisolone phosphate
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Betamethasone phosphate
Number of subjects: 0
Study: 31848294

Group type: EXPERIMENTAL
Intervention: Higher-dose NaHCO3 (HD-NaHCO3; 0.8 meq/kg of lean body wt per day)
Number of subjects: 194

Group type: EXPERIMENTAL
Intervention: Lower-dose NaHCO3 (LD-NaHCO3; 0.5 meq/kg of lean body wt per day)
Number of subjects: 194

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 194
Study: 29223700

Group type: EXPERIMENTAL
Intervention: USSRO
Number of subjects: 31

Group type: COMPARATOR
Intervention: BSSRO
Number of subjects: 31

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 31
Study: 27247409

Group type: EXPERIMENTAL
Intervention: Lay theory intervention
Number of subjects: 9500

Group type: COMPARATOR
Intervention: Control materials
Number of subjects: 9500
Study: 25449853

Group type: EXPERIMENTAL
Intervention: Endurance-Strength (ES)
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: Strength-Endurance (SE)
Number of subjects: 36

Group type: COMPARATOR
Intervention: Control (CON)
Number of subjects: 36
Study: 23034266

Group type: EXPERIMENTAL
Intervention: Oxygen and Ozone injections
Number of subjects: 38

Group type: COMPARATOR
Intervention: Pharmacological anti-inflammatory treatment
Number of subjects: 38
Study: 20484757

Group type: EXPERIMENTAL
Intervention: Hispanic girls engaged in 21.7 minutes of MVPA per day; Perceived transportation barriers positively related to MVPA (+; P = .010)
Number of subjects: 1180

Group type: EXPERIMENTAL
Intervention: Black girls engaged in 19.5 minutes of MVPA per day; BMI negatively related to MVPA (‐; P = .005), social support from friends positively related to MVPA (+; P = .006)
Number of subjects: 1180

Group type: EXPERIMENTAL
Intervention: White girls engaged in 22.8 minutes of MVPA per day; BMI negatively related to MVPA (‐; P < .001), barriers negatively related to MVPA (‐; P = .012), social support from friends positively related to MVPA (+; P = .010), participation in school sports positively related to MVPA (+; P = .009), community sports positively related to MVPA (+; P = .025)
Number of subjects: 1180
Study: 18194116

Group type: EXPERIMENTAL
Intervention: Prednisolone, cyclosporine, and sirolimus for 3 months followed by mycophenolate mofetil
Number of subjects: 113

Group type: COMPARATOR
Intervention: Prednisolone, cyclosporine, and mycophenolate mofetil throughout the study
Number of subjects: 113
Study: 16190913

Group type: EXPERIMENTAL
Intervention: IndoProCaf
Number of subjects: 54

Group type: COMPARATOR
Intervention: nimesulide
Number of subjects: 54
Study: 11833029

Group type: EXPERIMENTAL
Intervention: Ankle-foot orthosis (AFO)
Number of subjects: 43
Study: 10333017

Group type: EXPERIMENTAL
Intervention: Skeletonized ITA grafts (n = 40)
Number of subjects: 80

Group type: COMPARATOR
Intervention: Pedicled ITA grafts (n = 40)
Number of subjects: 80
Study: 7473908

Group type: EXPERIMENTAL
Intervention: Pneumatic antishock garment (PASG)
Number of subjects: 248

Group type: COMPARATOR
Intervention: No-PASG
Number of subjects: 248

Group type: EXPERIMENTAL
Intervention: Pneumatic antishock garment (PASG) in blunt trauma subset
Number of subjects: 248
Study: 1693038

Group type: EXPERIMENTAL
Intervention: Allylestrenol (ALE) 50 mg daily for 12 weeks
Number of subjects: 116

Group type: COMPARATOR
Intervention: Chlormadinone acetate (CMA) 50 mg daily for 12 weeks
Number of subjects: 116
Study: 7193005

Group type: EXPERIMENTAL
Intervention: 10 mg bromopride
Number of subjects: 10

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10
Study: 31985301

Group type: EXPERIMENTAL
Intervention: Calcipotriene 0.005%/betamethasone dipropionate 0.064% foam (Cal/BD)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Halobetasol 0.01%/tazarotene 0.045% lotion (HP/TAZ)
Number of subjects: 0
Study: 31205681

Group type: EXPERIMENTAL
Intervention: Mild adverse events after manual therapy in men
Number of subjects: 771

Group type: EXPERIMENTAL
Intervention: Moderate adverse events after manual therapy
Number of subjects: 771

Group type: COMPARATOR
Intervention: No adverse events after manual therapy
Number of subjects: 771
Study: 28044449

Group type: EXPERIMENTAL
Intervention: Curves Complete 90‐day Challenge (CC, n = 29)
Number of subjects: 133

Group type: EXPERIMENTAL
Intervention: Weight Watchers Points Plus (WW, n = 29)
Number of subjects: 133

Group type: EXPERIMENTAL
Intervention: Jenny Craig At Home (JC, n = 27)
Number of subjects: 133

Group type: EXPERIMENTAL
Intervention: Nutrisystem Advance Select (NS, n = 28)
Number of subjects: 133

Group type: COMPARATOR
Intervention: Control (n = 20)
Number of subjects: 133
Study: 26990279

Group type: EXPERIMENTAL
Intervention: Tele‐CBT (6 sessions)
Number of subjects: 47

Group type: COMPARATOR
Intervention: Standard preoperative care
Number of subjects: 47
Study: 23937421

Group type: EXPERIMENTAL
Intervention: Bazedoxifene 20 mg
Number of subjects: 8075

Group type: EXPERIMENTAL
Intervention: Bazedoxifene 40 mg
Number of subjects: 8075

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 8075

Group type: COMPARATOR
Intervention: Raloxifene 60 mg
Number of subjects: 8075
Study: 23534319

Group type: EXPERIMENTAL
Intervention: Mineral Trioxide Aggregate (MTA)
Number of subjects: 70

Group type: COMPARATOR
Intervention: Formocresol (FC)
Number of subjects: 70
Study: 19559543

Group type: EXPERIMENTAL
Intervention: Injection drug use behaviors (including methamphetamine and heroin use)
Number of subjects: 3285

Group type: EXPERIMENTAL
Intervention: Race/ethnicity (NH black, Hispanic, other/mixed)
Number of subjects: 3285

Group type: EXPERIMENTAL
Intervention: Sexual practices (males who only had sex with males)
Number of subjects: 3285

Group type: EXPERIMENTAL
Intervention: Injecting methamphetamine alone or with heroin
Number of subjects: 3285

Group type: EXPERIMENTAL
Intervention: Inconsistent means of obtaining income
Number of subjects: 3285

Group type: EXPERIMENTAL
Intervention: History of exchanging sex for money/drugs
Number of subjects: 3285
Study: 17430984

Group type: EXPERIMENTAL
Intervention: 200 mg mifepristone
Number of subjects: 22

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 22
Study: 16429184

Group type: COMPARATOR
Intervention: Control group (teeth with custom cast post and core)
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Group 2 (teeth without remaining coronal structure)
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Group 3 (teeth with 1 mm of remaining coronal structure)
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Group 4 (teeth with 2 mm of remaining coronal structure)
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Group 5 (teeth with 3 mm of remaining coronal structure)
Number of subjects: 50
Study: 11867507

Group type: EXPERIMENTAL
Intervention: 100 mg of isoflavones per day
Number of subjects: 34

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 34
Study: 10468094

Group type: EXPERIMENTAL
Intervention: Vasoactive therapy
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 0
Study: 1352246

Group type: EXPERIMENTAL
Intervention: ipsapirone 5 mg
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: ipsapirone 10 mg
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: ipsapirone (5-30 mg per day)
Number of subjects: 6

Group type: COMPARATOR
Intervention: placebo
Number of subjects: 6
Study: 6709431

Group type: EXPERIMENTAL
Intervention: Isoproterenol aerosol 0.1% inhalation
Number of subjects: 10

Group type: COMPARATOR
Intervention: Saline aerosol placebo
Number of subjects: 10
Study: 30527750

Group type: EXPERIMENTAL
Intervention: Cognitive impairment group
Number of subjects: 412
Study: 30037035

Group type: EXPERIMENTAL
Intervention: Iron deficiency
Number of subjects: 836
Study: 27277368

Group type: EXPERIMENTAL
Intervention: Pharmacological management with education
Number of subjects: 80

Group type: COMPARATOR
Intervention: Pharmacological management only
Number of subjects: 80
Study: 25703908

Group type: EXPERIMENTAL
Intervention: 0.1 mg/kg IM morphine and 60 μg of sublingual desmopressin melt
Number of subjects: 81

Group type: COMPARATOR
Intervention: 0.1 mg/kg IM morphine
Number of subjects: 81
Study: 23625867

Group type: EXPERIMENTAL
Intervention: Individualized heparin and protamine (HMS group, n=29)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Standard dose (ACT group, n=24)
Number of subjects: 60
Study: 20505152

Group type: EXPERIMENTAL
Intervention: Chemoradiotherapy plus AE-941
Number of subjects: 379

Group type: COMPARATOR
Intervention: Chemoradiotherapy plus placebo
Number of subjects: 379
Study: 18539869

Group type: EXPERIMENTAL
Intervention: Acetaminophen alternated with ibuprofen
Number of subjects: 38

Group type: COMPARATOR
Intervention: Acetaminophen alone
Number of subjects: 38
Study: 16377643

Group type: EXPERIMENTAL
Intervention: Didgeridoo lessons and daily practice at home for four months
Number of subjects: 25

Group type: COMPARATOR
Intervention: Control group (waiting list for lessons)
Number of subjects: 25
Study: 14645637

Group type: EXPERIMENTAL
Intervention: Inhaled nitric oxide (10 ppm on day 1, followed by 5 ppm for six days)
Number of subjects: 207

Group type: COMPARATOR
Intervention: Inhaled oxygen placebo
Number of subjects: 207

Group type: EXPERIMENTAL
Intervention: Inhaled nitric oxide
Number of subjects: 207
Study: 10885556

Group type: EXPERIMENTAL
Intervention: Laparoscopic antireflux surgery
Number of subjects: 0

Group type: COMPARATOR
Intervention: Open antireflux surgery
Number of subjects: 0
Study: 9471919

Group type: EXPERIMENTAL
Intervention: Screw fixation
Number of subjects: 101

Group type: COMPARATOR
Intervention: Kirschner's wire fixation
Number of subjects: 101
Study: 8509566

Group type: EXPERIMENTAL
Intervention: Captopril (6.25 mg initial dose, followed by 12.5 mg 2 hours later and continuing with 12.5 mg three times daily)
Number of subjects: 81

Group type: EXPERIMENTAL
Intervention: Isosorbide mononitrate (initial dose 20 mg followed by 20 mg three times daily)
Number of subjects: 81

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 81
Study: 3030173

Group type: EXPERIMENTAL
Intervention: Fish oil supplementation (2.7 g eicosapentaenoic acid and 1.8 g docosahexaenoic acid in 15 MAX-EPA capsules)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Placebo (identical-appearing capsules)
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Fish oil supplementation
Number of subjects: 40
Study: 28941303

Group type: EXPERIMENTAL
Intervention: Connective tissue graft from the maxillary tuberosity (n = 30, test group)
Number of subjects: 60

Group type: COMPARATOR
Intervention: No graft (n = 30, control group)
Number of subjects: 60
Study: 26272278

Group type: EXPERIMENTAL
Intervention: Aboral pouch reconstruction (AP)
Number of subjects: 100

Group type: COMPARATOR
Intervention: Roux-en-Y (RY)
Number of subjects: 100
Study: 24205951

Group type: EXPERIMENTAL
Intervention: 5 g/day of xylitol (5 lozenges of 1 g each, spaced throughout the day)
Number of subjects: 538

Group type: COMPARATOR
Intervention: Sucralose placebo
Number of subjects: 538
Study: 22729789

Group type: EXPERIMENTAL
Intervention: SS‐QoL‐12 (Stroke-Specific Quality of Life Scale)
Number of subjects: 126
Study: 20479241

Group type: EXPERIMENTAL
Intervention: Anthropocentric perspective in urban 5-year-olds
Number of subjects: 2

Group type: EXPERIMENTAL
Intervention: Reasoning in 3-year-olds
Number of subjects: 2
Study: 18545176

Group type: EXPERIMENTAL
Intervention: Dynamic stretching warm-up (DWU)
Number of subjects: 24

Group type: COMPARATOR
Intervention: Static stretching warm-up (SWU)
Number of subjects: 24
Study: 15867235

Group type: EXPERIMENTAL
Intervention: Vaccine plus radiotherapy
Number of subjects: 30

Group type: COMPARATOR
Intervention: Radiotherapy only
Number of subjects: 30
Study: 12673406

Group type: EXPERIMENTAL
Intervention: Itraconazole (200 mg twice daily)
Number of subjects: 61

Group type: COMPARATOR
Intervention: Control (no itraconazole)
Number of subjects: 61
Study: 10594393

Group type: EXPERIMENTAL
Intervention: Ursodeoxycholic acid (10 mg/kg per day in two divided doses for 1 month)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study: 8911886

Group type: EXPERIMENTAL
Intervention: Immediate release fluphenazine (12 mg)
Number of subjects: 14

Group type: EXPERIMENTAL
Intervention: Slow release fluphenazine (12 mg)
Number of subjects: 14

Group type: EXPERIMENTAL
Intervention: Intravenous bolus fluphenazine (2.5 mg)
Number of subjects: 14
Study: 1530416

Group type: EXPERIMENTAL
Intervention: Direct coronary angioplasty
Number of subjects: 0
Study: 6140022

Group type: EXPERIMENTAL
Intervention: Light breakfast
Number of subjects: 45

Group type: COMPARATOR
Intervention: Fasted overnight
Number of subjects: 45
Study: 31817564

Group type: EXPERIMENTAL
Intervention: MyPlate + NOVA intervention
Number of subjects: 0

Group type: COMPARATOR
Intervention: MyPlate intervention
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 0
Study: 29924426

Group type: EXPERIMENTAL
Intervention: Cognitive Processing Therapy (CPT)
Number of subjects: 266
Study: 27481855

Group type: EXPERIMENTAL
Intervention: Propofol dosing based on total body weight
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Propofol dosing based on lean body weight (LBW)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Propofol pharmacodynamics (PD) measured by the bispectral index
Number of subjects: 0
Study: 24398339

Group type: EXPERIMENTAL
Intervention: Telavancin
Number of subjects: 1266

Group type: COMPARATOR
Intervention: Vancomycin
Number of subjects: 1266

Group type: EXPERIMENTAL
Intervention: Telavancin and Vancomycin
Number of subjects: 1266
Study: 22829102

Group type: EXPERIMENTAL
Intervention: Letrozole 2.5 mg/day from cycle day 3 to 7
Number of subjects: 270

Group type: COMPARATOR
Intervention: Clomiphene citrate (CC) 100 mg/day from cycle day 3 to 7
Number of subjects: 270

Group type: EXPERIMENTAL
Intervention: Letrozole
Number of subjects: 270

Group type: COMPARATOR
Intervention: Clomiphene citrate (CC)
Number of subjects: 270
Study: 19225417

Group type: EXPERIMENTAL
Intervention: Guideline-based care (GBC) by occupational physicians
Number of subjects: 240

Group type: COMPARATOR
Intervention: Usual care (UC) with easy access to a psychologist
Number of subjects: 240

Group type: EXPERIMENTAL
Intervention: Guideline-based care (GBC)
Number of subjects: 240
Study: 17599856

Group type: EXPERIMENTAL
Intervention: Epoetin alfa 10,000 U once weekly (QW)
Number of subjects: 445

Group type: EXPERIMENTAL
Intervention: Epoetin alfa 20,000 U every 2 weeks (Q2W)
Number of subjects: 445

Group type: EXPERIMENTAL
Intervention: Epoetin alfa 30,000 U every 3 weeks (Q3W)
Number of subjects: 445

Group type: EXPERIMENTAL
Intervention: Epoetin alfa 40,000 U every 4 weeks (Q4W)
Number of subjects: 445
Study: 15727086

Group type: EXPERIMENTAL
Intervention: Extensive, ambulatory, non‐pharmacological obesity treatment programme
Number of subjects: 37

Group type: COMPARATOR
Intervention: Control group (GK)
Number of subjects: 37
Study: 12174105

Group type: EXPERIMENTAL
Intervention: Combined formulation once daily
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Combined formulation twice daily
Number of subjects: 0

Group type: COMPARATOR
Intervention: Calcipotriol twice daily
Number of subjects: 0

Group type: COMPARATOR
Intervention: Vehicle twice daily
Number of subjects: 0
Study: 9798076

Group type: EXPERIMENTAL
Intervention: Risperidone
Number of subjects: 56

Group type: COMPARATOR
Intervention: Haloperidol
Number of subjects: 56
Study: 7642857

Group type: EXPERIMENTAL
Intervention: Streptokinase plus intravenous heparin
Number of subjects: 2972

Group type: EXPERIMENTAL
Intervention: Streptokinase plus subcutaneous heparin
Number of subjects: 2972

Group type: EXPERIMENTAL
Intervention: Accelerated recombinant tissue-type plasminogen activator (rt-PA) plus intravenous heparin
Number of subjects: 2972

Group type: EXPERIMENTAL
Intervention: Streptokinase and rt-PA plus intravenous heparin
Number of subjects: 2972

Group type: EXPERIMENTAL
Intervention: Angioplasty
Number of subjects: 2972

Group type: COMPARATOR
Intervention: Shock (general outcome)
Number of subjects: 2972
Study: 2614491

Group type: EXPERIMENTAL
Intervention: Doxycycline
Number of subjects: 75

Group type: COMPARATOR
Intervention: Penicillin G
Number of subjects: 75
Study: 1124659

Group type: EXPERIMENTAL
Intervention: 20 mg iron as ferrous carbonate once daily
Number of subjects: 27

Group type: EXPERIMENTAL
Intervention: 100 mg iron as ferrous carbonate once daily
Number of subjects: 27

Group type: COMPARATOR
Intervention: No iron supplementation (Control)
Number of subjects: 27
Study: 30893060

Group type: EXPERIMENTAL
Intervention: Cognitive behavior therapy (CBT)-based multimodal pain rehabilitation program (PRP)
Number of subjects: 52
Study: 28931981

Group type: EXPERIMENTAL
Intervention: Inspiratory muscle training
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Low level laser (LLL) acupuncture stimulation
Number of subjects: 40
Study: 23490405

Group type: EXPERIMENTAL
Intervention: Carotid endarterectomy + optimal medical therapy
Number of subjects: 0

Group type: COMPARATOR
Intervention: Optimal medical therapy alone
Number of subjects: 0
Study: 23288035

Group type: EXPERIMENTAL
Intervention: TYR-free amino acid mixture (isoleucine 15 g, leucine 22.5 g, valine 17.5 g, lysine 17.5 g, methionine 5 g, threonine 10 g, tryptophan 2.5 g)
Number of subjects: 8

Group type: COMPARATOR
Intervention: Balanced mixture (BAL; TYR-free plus 12.5 g tyrosine and 12.5 g phenylalanine)
Number of subjects: 8
Study: 21680138

Group type: EXPERIMENTAL
Intervention: Ceramic-ceramic
Number of subjects: 357

Group type: COMPARATOR
Intervention: Ceramic-polyethylene
Number of subjects: 357
Study: 18095022

Group type: EXPERIMENTAL
Intervention: Oral prednisone (50 mg)
Number of subjects: 200

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 200
Study: 16543255

Group type: EXPERIMENTAL
Intervention: Clomiphene citrate 100 mg/day + Dexamethazone 2 mg/day
Number of subjects: 80

Group type: COMPARATOR
Intervention: Clomiphene citrate 100 mg/day + Placebo (folic acid tablets)
Number of subjects: 80
Study: 14557016

Group type: EXPERIMENTAL
Intervention: Bilateral ligation of the ascending branches of the uterine artery (Group 1, n=26)
Number of subjects: 51

Group type: COMPARATOR
Intervention: Intra-operative tourniquet method (Group 2, n=25)
Number of subjects: 51

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 51
Study: 10793594

Group type: EXPERIMENTAL
Intervention: i.v. tramadol 2 mg kg‐1 (n = 9)
Number of subjects: 14

Group type: EXPERIMENTAL
Intervention: caudal epidural tramadol 2 mg kg‐1 (n = 5)
Number of subjects: 14

Group type: COMPARATOR
Intervention: caudal tramadol
Number of subjects: 14
Study: 8614385

Group type: EXPERIMENTAL
Intervention: IV Methotrexate (MTX) 500 mg/m2 infused over 24 hours, three times during consolidation and every 6 weeks during maintenance
Number of subjects: 164

Group type: COMPARATOR
Intervention: Oral Methotrexate (MTX) 20 mg/m2/week
Number of subjects: 164

Group type: EXPERIMENTAL
Intervention: Both IV and oral MTX
Number of subjects: 164
Study: 1451343

Group type: EXPERIMENTAL
Intervention: Folic acid supplementation withdrawn at the start of the study (Group 1)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Folic acid supplementation continued for 12 months (Group 2)
Number of subjects: 20
Study: 31996114

Group type: EXPERIMENTAL
Intervention: Longitudinal remote coaching (LRC)
Number of subjects: 3

Group type: COMPARATOR
Intervention: Collaborative care model (CoCM)
Number of subjects: 3